Junction, GRAIL Enable Scalable Access to Multi-Cancer Detection Test

Through Junction’s diagnostic infrastructure, healthcare providers can integrate Galleri into existing workflows with a single, unified ordering experience, an embedded physician network, and operational support adapted for complex testing. The approach is designed to make MCED ordering and follow-up consistent across varied care models.

Galleri is a blood test designed to detect a signal shared by more than 50 cancer types, many of which do not have recommended screening options. By connecting Galleri to Junction’s infrastructure, organizations can incorporate this MCED testing into routine clinical operations without building bespoke systems. The integration is positioned to help teams standardize how testing is requested, reviewed, and returned within provider and patient experiences.

Under the collaboration, organizations can order the Galleri test directly through Junction, support multi-state clinical operations, manage workflows for complex testing, and streamline both patient and provider interactions. The integration also includes enhanced physician follow-up calls with patients, helping to close the loop on test results and next steps within the same infrastructure. Collectively, these functions aim to reduce administrative burden while maintaining consistency in test utilization.

Junction’s platform provides the infrastructure for diagnostic testing and health data workflows, offering a single application programming interface to integrate laboratory testing, wearable device data, and diagnostics into clinical products. The platform manages tasks from ordering and specimen coordination to receipt of standardized results and continuous data streaming, allowing healthcare teams to embed reliable diagnostics at scale.

“As demand for proactive and preventative care grows, platforms need reliable infrastructure to operationalize advanced diagnostics at scale,” said Maitham Dib, Junction’s Founder. “Our collaboration with GRAIL helps bring Galleri into real-world care models more efficiently.”

“Single-cancer screenings are an important tool for detection and diagnosis of five cancers in the U.S, but 70% of cancer deaths are caused by cancers without recommended screening tests. GRAIL is excited to collaborate with Junction to broaden access to the Galleri multi-cancer early detection test through a streamlined experience for healthcare organizations and prescribing providers,” said Megan Hall, Ph.D., vice president of Medical Affairs at GRAIL. "Junction's infrastructure helps simplify the operational steps around offering Galleri, making it easier for providers to integrate the test into care delivery."